The intestinal microbiome as a predictive biomarker for efficacy and side effects of CAR-T cell therapy in blood cancers

ABSTRACT: Interventions: Group 1: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and patients with relapsed or refractory acute lymphocytic leukemia (ALL) who have been selected for treatment with CD19-targeting CAR-T cells will be recruited. Stool samples are collected at multiple timepoints (before lymphodepletion, before T-cell infusion, and after T-cell infusion). Primary outcome(s): The main outcome is bacterial alpha diversity according to Simpson (AD) at the time of CAR-T cell therapy, which should be associated with survival within 24 months. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment

DISEASE(S): Acute Lymphoblastic Leukaemia [all],Diffuse Large B-cell Lymphoma

PROVIDER: 2436511 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR